Dupilumab Extended Interval Dosing in Chronic Rhinosinusitis With Nasal Polyps: A Systematic Review and Meta-analysis.
Otolaryngol Head Neck SurgJun 15, 2026 (epub)
Abdulsalam Alqutub, Amr I Herzallah, Sulafa Alqutub et al.
✦ AI-curated · Sources linked
In 30 seconds
This systematic review and meta-analysis evaluated the effects of extending dupilumab dosing intervals beyond the standard every-two-weeks regimen in adults with chronic rhinosinusitis with nasal polyps. The analysis included 19 studies and found that extending the interval to every four weeks maintained disease control, with a significant decrease in eosinophils (-0.13 × 10 9 /L; P = .047).
Key findings
- Extended interval dosing preserved disease control in chronic rhinosinusitis with nasal polyps.
- Eosinophils decreased significantly with extended dosing (-0.13 × 10 9 /L; P = .047).
- No significant changes were observed in SNOT-22 scores or nasal polyp scores with Q4W dosing.
- Real-world studies suggest feasibility of further extending intervals to Q6W-Q12W.
Why it matters
Understanding the efficacy of extended dosing intervals for dupilumab can help clinicians optimize treatment regimens for patients with chronic rhinosinusitis with nasal polyps, potentially improving patient adherence and outcomes.